Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neurogene (NGNE) EPS (Weighted Average and Diluted): 2018-2025

Historic EPS (Weighted Average and Diluted) for Neurogene (NGNE) over the last 3 years, with Sep 2025 value amounting to -$0.99.

  • Neurogene's EPS (Weighted Average and Diluted) rose 16.81% to -$0.99 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.11, marking a year-over-year decrease of 1074.29%. This contributed to the annual value of -$4.28 for FY2024, which is 62.15% up from last year.
  • Latest data reveals that Neurogene reported EPS (Weighted Average and Diluted) of -$0.99 as of Q3 2025, which was up 5.71% from -$1.05 recorded in Q2 2025.
  • Over the past 5 years, Neurogene's EPS (Weighted Average and Diluted) peaked at $2.93 during Q4 2023, and registered a low of -$32.67 during Q3 2023.
  • Moreover, its 3-year median value for EPS (Weighted Average and Diluted) was -$1.08 (2025), whereas its average is -$8.37.
  • Examining YoY changes over the last 5 years, Neurogene's EPS (Weighted Average and Diluted) showed a top increase of 96.46% in 2024 and a maximum decrease of 133.79% in 2024.
  • Neurogene's EPS (Weighted Average and Diluted) (Quarterly) stood at $2.93 in 2023, then crashed by 133.79% to -$0.99 in 2024, then grew by 16.81% to -$0.99 in 2025.
  • Its EPS (Weighted Average and Diluted) was -$0.99 in Q3 2025, compared to -$1.05 in Q2 2025 and -$1.08 in Q1 2025.